The treatment of head and neck squamous cell carcinoma (HNSCC) is set to undergo rapid changes, as molecular targeted therapy continues to make strides. HNSCCs are characterized by substantial ...
The multitargeted tyrosine kinase inhibitor (MKI), lenvatinib, is widely used to treat advanced and metastatic thyroid cancer. However, the molecular mechanisms by which thyroid cancer cells become ...
Edward Arrowsmith, MD, MPH, medical director for clinical pathways for OneOncology, discussed treatment challenges in EGFR Exon 20 insertion+ non-small cell lung cancer (NSCLC) and best practices in ...
Suresh Ramalingam, MD, FACP, FASCO, a professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, is the executive director of the Winship Cancer Institute ...
The dual inhibition of PD-1 and VEGF pathways by ivonescimab aims to enhance immune response and limit tumor angiogenesis, ...
Clinical relevance of insulin regulatory pathways in non-small cell lung cancer (NSCLC) progression.
Impact of EGFR and KRAS mutations on survival in 1,000 patients with resected lung adenocarcinoma. Background: Insulin and insulin-like growth factors are key regulators of normal metabolism and ...
First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment - ...
SurvivorNet on MSN
Targeted therapy in a shot: New approval for EGFR-mutated lung cancer can improve day-to-day life for patients
Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback